Comparison of the outcomes of ileal pouch-anal anastomosis and ileorectal anastomosis for patients with familial adenomatous polyposis: a systematic review and meta-analysis.

J Gastrointest SurgAug 13, 2026 (epub)
Clinical ResearchGastroenterologyOncology (Medical)

Phuong Minh Tang, Bui Thien Nghiep Vo, Tung-Cheng Chang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated outcomes of ileal pouch-anal anastomosis (IPAA) versus ileorectal anastomosis (IRA) in 4700 patients with familial adenomatous polyposis. IPAA was linked to a significantly lower risk of postoperative rectal and pouch-anal cancer (RR, 0.22) but a higher risk of desmoid tumors (RR, 1.58) and worse bowel function.

Key findings

  • IPAA was associated with a lower risk of postoperative rectal and pouch-anal cancer (RR, 0.22).
  • Patients undergoing IPAA had a higher risk of desmoid tumors (RR, 1.58).
  • IPAA resulted in higher rates of 24-hour incontinence (RR, 1.90) and stool frequency (MD, 1.89 stools/d).
  • Anastomotic stricture occurred more frequently after IPAA (RR, 2.91).

Why it matters

Understanding the trade-offs between IPAA and IRA is crucial for clinicians in making informed decisions regarding surgical options for patients with familial adenomatous polyposis, balancing oncologic outcomes with functional implications.

Source

PubMed · PMID 42594997

Published in J Gastrointest Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.